[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @TOWiU2 MASi MASi posts on X about $dcth, $hrow, $zlab, $srpt the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1132559626065592321/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +93% - X Year XXXXXXX +161% ### Mentions: XX [#](/creator/twitter::1132559626065592321/posts_active)  - X Week XX +28% - X Month XX -XX% - X Months XXX +48% - X Year XXX +170% ### Followers: XXXXX [#](/creator/twitter::1132559626065592321/followers)  - X Week XXXXX +0.07% - X Month XXXXX +1.10% - X Months XXXXX +6.60% - X Year XXXXX +5.90% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1132559626065592321/influencer_rank)  ### Social Influence [#](/creator/twitter::1132559626065592321/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [travel destinations](/list/travel-destinations) XXXX% [countries](/list/countries) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [$dcth](/topic/$dcth) #11, [$hrow](/topic/$hrow) #18, [$zlab](/topic/$zlab) #7, [$srpt](/topic/$srpt) #43, [$vktx](/topic/$vktx) #28, [$cytk](/topic/$cytk) #5, [$idya](/topic/$idya) #13, [$ntla](/topic/$ntla) #26, [$qure](/topic/$qure) #19, [$sgmo](/topic/$sgmo) #11 **Top accounts mentioned or mentioned by** [@biohazard3737](/creator/undefined) [@feldtinvesting](/creator/undefined) [@jfais20](/creator/undefined) [@ltbioinvestor](/creator/undefined) [@jayabacus](/creator/undefined) [@mohamma38710129](/creator/undefined) [@rnaianalyst](/creator/undefined) [@behaviorfin](/creator/undefined) [@duedoctor](/creator/undefined) [@dmitrykovalchuk](/creator/undefined) [@merck](/creator/undefined) [@snupsnus](/creator/undefined) [@johnbresnahan](/creator/undefined) [@pick19982](/creator/undefined) [@webcrawlervers](/creator/undefined) [@gjtennis](/creator/undefined) [@judguy](/creator/undefined) [@propthinker](/creator/undefined) [@chrisolin](/creator/undefined) [@nightowlbiotech](/creator/undefined) **Top assets mentioned** [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [uniQure N.V. (QURE)](/topic/$qure) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Biogen Inc (BIIB)](/topic/$biib) ### Top Social Posts [#](/creator/twitter::1132559626065592321/posts) --- Top posts by engagements in the last XX hours "@Biohazard3737 $HROW $ZLAB Week XX after Poll:" [X Link](https://x.com/TOWiU2/status/1979281811571085326) [@TOWiU2](/creator/x/TOWiU2) 2025-10-17T20:22Z 1449 followers, XXX engagements "@ShortShitStocks Typical in my book would be Lonza BI or SBL. If form & fill Vetter or Siegfried. But Im not familiar with any "atypical-biotech-CMC"" [X Link](https://x.com/TOWiU2/status/1973048477782253867) [@TOWiU2](/creator/x/TOWiU2) 2025-09-30T15:33Z 1450 followers, XX engagements "@Biohazard3737 $HROW $ZLAB Week XX after Poll:" [X Link](https://x.com/TOWiU2/status/1974219576847012083) [@TOWiU2](/creator/x/TOWiU2) 2025-10-03T21:06Z 1450 followers, XXX engagements "$SRPT will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress taking place Oct. 7-11 2025 in Vienna Austria" [X Link](https://x.com/TOWiU2/status/1974787096608145743) [@TOWiU2](/creator/x/TOWiU2) 2025-10-05T10:41Z 1450 followers, 1980 engagements "@Biohazard3737 $HROW $ZLAB Week XX after Poll:" [X Link](https://x.com/TOWiU2/status/1976767559211917530) [@TOWiU2](/creator/x/TOWiU2) 2025-10-10T21:51Z 1450 followers, XXX engagements "@LTbioinvestor $VKTX $SRPT $CYTK $IDYA Week XX after Poll:" [X Link](https://x.com/TOWiU2/status/1976770673532968975) [@TOWiU2](/creator/x/TOWiU2) 2025-10-10T22:03Z 1450 followers, 1154 engagements "(3/N) ". liver metastases typically lead X poor outcomes when treated w systemic checkpoint inhibitors alone due X the livers immunosuppressive microenvironment $DCTH s ability X enhance immunotherapy efficacy may position the company @ the forefront of a new treatment class"" [X Link](https://x.com/TOWiU2/status/1979897735215010151) [@TOWiU2](/creator/x/TOWiU2) 2025-10-19T13:09Z 1449 followers, XXX engagements "$IONS $BIIB announced that the FDA issued a CRL for the Companys sNDA for the high dose regimen of nusinersen for the treatment of SMA. The FDA letter requested an update to the technical information be included in the CMC module of the sNDA" [X Link](https://x.com/TOWiU2/status/1970818434016395713) [@TOWiU2](/creator/x/TOWiU2) 2025-09-24T11:51Z 1449 followers, XXX engagements "@BehaviorFin $NTLA $QURE $SGMO $ADAP Week XX after Poll:" [X Link](https://x.com/TOWiU2/status/1976769019203207310) [@TOWiU2](/creator/x/TOWiU2) 2025-10-10T21:57Z 1449 followers, 1539 engagements "@LTbioinvestor $VKTX $SRPT $CYTK $IDYA Week XX after Poll:" [X Link](https://x.com/TOWiU2/status/1979285242289496188) [@TOWiU2](/creator/x/TOWiU2) 2025-10-17T20:35Z 1449 followers, 1065 engagements "$DCTH Prelim 3rd Q 2025 Financial Results Total CHEMOSAT & HEPZATO KIT rev of approx $20.5m HEPZATO KIT rev $19.2m CHEMOSAT rev $XXX Gross margins expected to be XX% Net income of $XXX million Pos adj EBITDA of $5.3m Pos op cashflow of $4.8m" [X Link](https://x.com/TOWiU2/status/1979652751346020559) [@TOWiU2](/creator/x/TOWiU2) 2025-10-18T20:56Z 1449 followers, 1230 engagements "@PrivacySetting1 @BJLinvestment "the idea that it even remotely matters whether they do $XX or $XX or $XX million of revenue this quarter" It is part of the $169m that $HROW still has to deliver in 2025 to meet its own guidance which is important for mgmt's credibility. From this perspective it does matter" [X Link](https://x.com/TOWiU2/status/1977710211654648109) [@TOWiU2](/creator/x/TOWiU2) 2025-10-13T12:17Z 1449 followers, 2184 engagements "@BehaviorFin $NTLA $QURE $SGMO $ADAP Week XX after Poll:" [X Link](https://x.com/TOWiU2/status/1979283261315539180) [@TOWiU2](/creator/x/TOWiU2) 2025-10-17T20:27Z 1449 followers, 1580 engagements "$DCTH 2025 Full Year Financial Guidance Total CHEMOSAT & HEPZATO KIT revenue of $83m to $85m reflecting an approximate XXX% increase in treatment volume over 2024 Quarterly gross margins between XX% to XX% Positive adjusted EBITDA and operating cashflow in each quarter of 2025" [X Link](https://x.com/TOWiU2/status/1979653195015278878) [@TOWiU2](/creator/x/TOWiU2) 2025-10-18T20:57Z 1449 followers, XXX engagements "via @BioTechHealthX (1/N) "What sets $DCTH apart from traditional biotech companies is its drug-device hybrid model that creates durable competitive advantages and raises barriers to entry."" [X Link](https://x.com/TOWiU2/status/1979896779978985971) [@TOWiU2](/creator/x/TOWiU2) 2025-10-19T13:05Z 1449 followers, 1052 engagements "(4/4) "This could vastly expand its addressable market beyond uveal melanoma into much larger patient populations driving exponential revenue growth over the next decade." $DCTH" [X Link](https://x.com/TOWiU2/status/1979897915075178974) [@TOWiU2](/creator/x/TOWiU2) 2025-10-19T13:10Z 1449 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@TOWiU2 MASi
MASi posts on X about $dcth, $hrow, $zlab, $srpt the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +93%
- X Year XXXXXXX +161%
Mentions: XX #
- X Week XX +28%
- X Month XX -XX%
- X Months XXX +48%
- X Year XXX +170%
Followers: XXXXX #
- X Week XXXXX +0.07%
- X Month XXXXX +1.10%
- X Months XXXXX +6.60%
- X Year XXXXX +5.90%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXX% travel destinations XXXX% countries XXXX% finance XXXX%
Social topic influence $dcth #11, $hrow #18, $zlab #7, $srpt #43, $vktx #28, $cytk #5, $idya #13, $ntla #26, $qure #19, $sgmo #11
Top accounts mentioned or mentioned by @biohazard3737 @feldtinvesting @jfais20 @ltbioinvestor @jayabacus @mohamma38710129 @rnaianalyst @behaviorfin @duedoctor @dmitrykovalchuk @merck @snupsnus @johnbresnahan @pick19982 @webcrawlervers @gjtennis @judguy @propthinker @chrisolin @nightowlbiotech
Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Viking Therapeutics, Inc (VKTX) Cytokinetics Inc. (CYTK) IDEAYA Biosciences, Inc. Common Stock (IDYA) Intellia Therapeutics, Inc (NTLA) uniQure N.V. (QURE) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Biogen Inc (BIIB)
Top Social Posts #
Top posts by engagements in the last XX hours
"@Biohazard3737 $HROW $ZLAB Week XX after Poll:"
X Link @TOWiU2 2025-10-17T20:22Z 1449 followers, XXX engagements
"@ShortShitStocks Typical in my book would be Lonza BI or SBL. If form & fill Vetter or Siegfried. But Im not familiar with any "atypical-biotech-CMC""
X Link @TOWiU2 2025-09-30T15:33Z 1450 followers, XX engagements
"@Biohazard3737 $HROW $ZLAB Week XX after Poll:"
X Link @TOWiU2 2025-10-03T21:06Z 1450 followers, XXX engagements
"$SRPT will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress taking place Oct. 7-11 2025 in Vienna Austria"
X Link @TOWiU2 2025-10-05T10:41Z 1450 followers, 1980 engagements
"@Biohazard3737 $HROW $ZLAB Week XX after Poll:"
X Link @TOWiU2 2025-10-10T21:51Z 1450 followers, XXX engagements
"@LTbioinvestor $VKTX $SRPT $CYTK $IDYA Week XX after Poll:"
X Link @TOWiU2 2025-10-10T22:03Z 1450 followers, 1154 engagements
"(3/N) ". liver metastases typically lead X poor outcomes when treated w systemic checkpoint inhibitors alone due X the livers immunosuppressive microenvironment $DCTH s ability X enhance immunotherapy efficacy may position the company @ the forefront of a new treatment class""
X Link @TOWiU2 2025-10-19T13:09Z 1449 followers, XXX engagements
"$IONS $BIIB announced that the FDA issued a CRL for the Companys sNDA for the high dose regimen of nusinersen for the treatment of SMA. The FDA letter requested an update to the technical information be included in the CMC module of the sNDA"
X Link @TOWiU2 2025-09-24T11:51Z 1449 followers, XXX engagements
"@BehaviorFin $NTLA $QURE $SGMO $ADAP Week XX after Poll:"
X Link @TOWiU2 2025-10-10T21:57Z 1449 followers, 1539 engagements
"@LTbioinvestor $VKTX $SRPT $CYTK $IDYA Week XX after Poll:"
X Link @TOWiU2 2025-10-17T20:35Z 1449 followers, 1065 engagements
"$DCTH Prelim 3rd Q 2025 Financial Results Total CHEMOSAT & HEPZATO KIT rev of approx $20.5m HEPZATO KIT rev $19.2m CHEMOSAT rev $XXX Gross margins expected to be XX% Net income of $XXX million Pos adj EBITDA of $5.3m Pos op cashflow of $4.8m"
X Link @TOWiU2 2025-10-18T20:56Z 1449 followers, 1230 engagements
"@PrivacySetting1 @BJLinvestment "the idea that it even remotely matters whether they do $XX or $XX or $XX million of revenue this quarter" It is part of the $169m that $HROW still has to deliver in 2025 to meet its own guidance which is important for mgmt's credibility. From this perspective it does matter"
X Link @TOWiU2 2025-10-13T12:17Z 1449 followers, 2184 engagements
"@BehaviorFin $NTLA $QURE $SGMO $ADAP Week XX after Poll:"
X Link @TOWiU2 2025-10-17T20:27Z 1449 followers, 1580 engagements
"$DCTH 2025 Full Year Financial Guidance Total CHEMOSAT & HEPZATO KIT revenue of $83m to $85m reflecting an approximate XXX% increase in treatment volume over 2024 Quarterly gross margins between XX% to XX% Positive adjusted EBITDA and operating cashflow in each quarter of 2025"
X Link @TOWiU2 2025-10-18T20:57Z 1449 followers, XXX engagements
"via @BioTechHealthX (1/N) "What sets $DCTH apart from traditional biotech companies is its drug-device hybrid model that creates durable competitive advantages and raises barriers to entry.""
X Link @TOWiU2 2025-10-19T13:05Z 1449 followers, 1052 engagements
"(4/4) "This could vastly expand its addressable market beyond uveal melanoma into much larger patient populations driving exponential revenue growth over the next decade." $DCTH"
X Link @TOWiU2 2025-10-19T13:10Z 1449 followers, XXX engagements